Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The phase 2 trial published in The New England Journal of Medicine in 2023 enrolled adults with obesity without type 2 diabetes and demonstrated dose-dependent weight loss of up to 24.2% of body weight at the highest dose over 48 weeks results that attracted considerable scientific and media attention
Why this matters for drug discovery GLP-1 receptor biology explains why a single class of drugs can lower blood sugar, curb appetite, and protect the heart and kidneys at once
They may adjust timing or dosing
Join the GLP-1 Collective nonprofit to connect with the community, access resources, and see how patient voices are driving change
1 DPP-4 plays a role in glucose homoeostasis by increasing nutrient-stimulated insulin synthesis and by reducing glucagon secretion
Bupropion for Weight Loss: How It Compares to GLP-1 Medications Bupropion shows up in weight loss conversations more often than people expect, partly because its been around for decades and partly because it does produce modest weight loss in some patients
